| 001 | 120384 | ||
| 005 | 20240228135019.0 | ||
| 024 | 7 | _ | |a 10.1093/annonc/mdt511 |2 doi |
| 024 | 7 | _ | |a pmid:24356631 |2 pmid |
| 024 | 7 | _ | |a 0923-7534 |2 ISSN |
| 024 | 7 | _ | |a 1569-8041 |2 ISSN |
| 024 | 7 | _ | |a altmetric:2234266 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2017-00817 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Herth, I. |b 0 |
| 245 | _ | _ | |a The impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparison. |
| 260 | _ | _ | |a Oxford |c 2014 |b Oxford Univ. Press |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1520592729_3333 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a In a single-center retrospective donor versus no-donor comparison, we investigated if allogeneic stem cell transplantation (alloSCT) can improve the dismal course of poor-risk chronic lymphocytic leukemia (CLL).All patients with CLL who were referred for evaluation of alloSCT within a 7-year time frame and had a donor search indication according to the EBMT criteria or because of Richter's transformation were included. Patients for whom a matched donor could be found within 3 months (matches) were compared with patients without such a donor (controls). Primary end point was overall survival measured from the 3-month landmark after search initiation.Of 105 patients with donor search, 97 (matches 83; controls 14) were assessable at the 3-month landmark. Matches and controls were comparable for age, gender, time from diagnosis, number of previous regimens, and remission status. Disregarding if alloSCT was actually carried out or not, survival from the 3-month landmark was significantly better in matches versus controls [hazard ratio 0.38, 95% confidence interval (CI) 0.17-0.85; P = 0.014]. The survival benefit of matches remained significant on multivariate analysis.This study provides first comparative evidence that alloSCT may have the potential to improve the natural course of poor-risk CLL as defined by the EBMT criteria. |
| 536 | _ | _ | |a 317 - Translational cancer research (POF3-317) |0 G:(DE-HGF)POF3-317 |c POF3-317 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 700 | 1 | _ | |a Dietrich, Sascha |0 P:(DE-He78)6333b389d0abc96ef7f2f6e049a8f8c4 |b 1 |u dkfz |
| 700 | 1 | _ | |a Benner, Axel |0 P:(DE-He78)e15dfa1260625c69d6690a197392a994 |b 2 |u dkfz |
| 700 | 1 | _ | |a Hegenbart, U. |b 3 |
| 700 | 1 | _ | |a Rieger, M. |b 4 |
| 700 | 1 | _ | |a Stadtherr, P. |b 5 |
| 700 | 1 | _ | |a Bondong, A. |b 6 |
| 700 | 1 | _ | |a Tran, T. H. |b 7 |
| 700 | 1 | _ | |a Weide, R. |b 8 |
| 700 | 1 | _ | |a Hensel, M. |b 9 |
| 700 | 1 | _ | |a Knauf, W. |b 10 |
| 700 | 1 | _ | |a Franz-Werner, J. |b 11 |
| 700 | 1 | _ | |a Welslau, M. |b 12 |
| 700 | 1 | _ | |a Procaccianti, M. |b 13 |
| 700 | 1 | _ | |a Görner, M. |b 14 |
| 700 | 1 | _ | |a Meissner, J. |b 15 |
| 700 | 1 | _ | |a Luft, T. |b 16 |
| 700 | 1 | _ | |a Schönland, S. |b 17 |
| 700 | 1 | _ | |a Witzens-Harig, M. |b 18 |
| 700 | 1 | _ | |a Zenz, Thorsten |0 P:(DE-He78)f3d5f16b49eb47520def635be98d5576 |b 19 |u dkfz |
| 700 | 1 | _ | |a Ho, A. D. |b 20 |
| 700 | 1 | _ | |a Dreger, P. |b 21 |
| 773 | _ | _ | |a 10.1093/annonc/mdt511 |g Vol. 25, no. 1, p. 200 - 206 |0 PERI:(DE-600)2003498-2 |n 1 |p 200 - 206 |t Annals of oncology |v 25 |y 2014 |x 1569-8041 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:120384 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 1 |6 P:(DE-He78)6333b389d0abc96ef7f2f6e049a8f8c4 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)e15dfa1260625c69d6690a197392a994 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 19 |6 P:(DE-He78)f3d5f16b49eb47520def635be98d5576 |
| 913 | 1 | _ | |a DE-HGF |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-317 |2 G:(DE-HGF)POF3-300 |v Translational cancer research |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |b Gesundheit |
| 914 | 1 | _ | |y 2014 |
| 915 | _ | _ | |a Allianz-Lizenz / DFG |0 StatID:(DE-HGF)0400 |2 StatID |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b ANN ONCOL : 2015 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b ANN ONCOL : 2015 |
| 920 | 1 | _ | |0 I:(DE-He78)C060-20160331 |k C060 |l Biostatistik |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)G100-20160331 |k G100 |l Translationale Onkologie |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C060-20160331 |
| 980 | _ | _ | |a I:(DE-He78)G100-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::